Author Archives: Kate Murphy

Regorafenib Now Available Via Expanded Access

Click Here to Get updates from Fight Colorectal Cancer The first four sites where colorectal cancer patients can get regorafenib are now open.  Bayer Healthcare expects to open additional sites in the next two or three weeks. Colorectal cancer patients whose cancer has gotten worse on all standard treatments can now be considered for the Regorafenib Extended Access program. Bayer Healthcare has applied for FDA approval of regorafenib to treat colorectal cancer, but until it is actually approved and on the market, the expanded access program is the only way patients who might benefit can receive it. Last fall, early results from the randomized Phase 3 CORRECT clinical trial showed

Protect Kids from Fentanyl Pain Patches

The FDA reminds patients who use fentanyl patches for pain to take special care storing, using, and discarding them. Recently the FDA evaluated 26 cases of children’s accidents that involved the patches including 10 deaths and 12 hospitalizations. Sixteen children were under two years of age. Problems included curious children finding patches in the trash or stored within their reach. In addition, loose patches transferred the potent narcotic medicine to children who were being held or carried. Even used patches can still contain significant amounts of fentanyl, enough to seriously hurt a child. Before using either the brand name Duragesic® or generic fentanyl transdermal system patches, read the FDA approved

Dole Salad Salmonella Alert

Dole Fresh Vegetables is voluntarily recalling over 750 cases of DOLE® Seven Lettuces salad with Use-by Date of April 11, 2012. While no illness has yet been associated with eating the salads, a random sample collected by the State of New York found contamination with Salmonella. The recalled packages have a UPC code of 71430 01057 and Product Codes 0577N089112A and 0577N089112B. Consumers should check the codes and the use-by date and throw out any suspicious salads. Retailers are being told to check shelves for any remaining Dole Seven Lettuce salads and remove them. If you have questions, you can call the Dole Food Company Consumer Response Center at (800)

Giving Patients a Screening Choice Matters

When patients  were offered a choice of colorectal cancer screening with either FOBT or colonoscopy, they were significantly more likely to complete that screening than when their doctors recommended only FOBT or only colonoscopy. Nearly 1000 racially and ethnically diverse patients in urban primary care practices were randomly assigned to get colorectal cancer screening via: Fecal occult blood testing (FOBT) Colonoscopy, or Their choice of either FOBT or colonoscopy. Overall, 58 percent were screened within the next year. 

Do You Need that Test? Wise Choices from Gastroenterologists

How soon should average risk people get another colorectal cancer screening after they have a normal colonoscopy? No sooner than 10 years, the American Gastroenterological Association recommends as part of the Choosing Wisely campaign. The AGA’s list of Five Things Physicians and Patients Should Question includes: Use the lowest possible effective dose of acid reducing medicines to treat gastroesophageal reflux disease (GERD). After a negative, quality colonoscopy, don’t repeat colorectal cancer screening by any method for 10 years. After removing 1 or 2 small (less than 1 centimeter) adenomatous polyps without signs of cellular change (dysplasia), don’t repeat the colonoscopy for at least 5 years. After two endoscopies without dysplasia,

Choosing Wisely: What CancerTests and Treatments Do You Really Need?

Oncologists have joined eight other physician specialty organizations in the Choosing Wisely® campaign with a list of the Top Five Cancer-Related Tests, Procedures, and Treatments That Many Patients Do Not Need. Choosing Wisely asked each of the specialist groups to come up with a list of five things doctors and patients should question in order to improve evidence-based care, avoid tests or treatments that don’t help, and reduce the burden of health care costs. Here are the Top Five lists from the other groups. The American Society of Clinical Oncology  built the Top Five List for Oncology, based on work that ASCO’s Cost of Care Task Force has been doing

Disappointing Results for Perifosine

Perifosine was no better than a placebo in improving survival time for people with late-stage colorectal cancer according to a news release from Keryx Biopharmaceuticals. Despite success in a smaller Phase II clinical trial, the X-PECT Phase III trial failed to meet its primary objective — longer survival time. X-PECT randomized 468 patients to receive either: Xeloda® (capecitabine) plus perifosine, or Xeloda plus a placebo Although final details were not provided, the perifosine group did not live longer than the patients who got a dummy pill. Patients in the trial had refractory colorectal cancer, tumors that had already gotten worse on at least two standard chemotherapy regimens. Had perifosine helped

Fighting Crisis in Cancer Funding Named Number One Priority for AACR

The American Association for Cancer Research (AACR) says that declining budgets at the National Institutes of Health a crisis standing in the way of bringing cancer research to patient’s lives. For the past ten years, NIH budgets have been essentially flat.  Factoring in rising research costs, flat funding means a loss of nearly $6 billion dollars in purchasing power. AACR is calling on its members and the advocacy community to work even harder with Congress to invest in medical research.  The AACR board of directors said, Therefore, the AACR announced this morning that it plans to redouble its efforts to engage with Congress to make research funding a higher national

Watch Fight Colorectal Cancer Ring the NASDAQ Bell

Fight Colorectal Cancer President Carlea Bauman was joined by staff, survivors, advocates and fighters to “get behind a cure” and ring the NASDAQ closing bell. We ring the bell to bring attention that colorectal cancer is the number two cancer killer in America. We need awareness that colorectal cancer can be prevented, treated, and beaten. We are issuing a call to action to increase funding for research, better access to colorectal screening, and the very best treatment for every American who is diagnosed with colon or rectal cancer. On stage with Carlea was: Ben Basloe, Todd Jones, Josh Young, Rose Hausmann, Joanne Kimmel, Dana Rye, Katelyn Sherry and David Dubin.

March 22: Lynch Syndrome Hereditary Cancer Public Awareness Day

Fight those Cougars! Colon, ovarian, uterine, gastric, renal, and skin cancer. All Lynch syndrome related cancers, and all significantly increased in families with Lynch syndrome mutations. Brain and small bowel cancer risks are also higher. In addition, new evidence finds that pancreatic and breast cancer are also part of Lynch syndrome. Today, people living with Lynch syndrome come together with researchers, genetic counselors, and healthcare professionals to spread the word that Lynch syndrome can be managed. But first it needs to be recognized. Awareness saves lives. Careful family histories and routine testing after surgery can identify people who have one of the genes that cause Lynch syndrome. When you find